<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622917</url>
  </required_header>
  <id_info>
    <org_study_id>791-792</org_study_id>
    <nct_id>NCT04622917</nct_id>
  </id_info>
  <brief_title>Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.</brief_title>
  <official_title>Is the Effect of Systemic Steroids Treating Pollen Induced Allergic Rhinitis Mainly Due to a Placebo Effect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of intramuscular injected methylprednisolone treating birch&#xD;
      pollen induced rhinitis compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was an interventional single center double-blinded human randomized trial with two&#xD;
      groups treated parallel.The first group received an intramuscular injection of&#xD;
      Methylprednisolone 40 mg/ml 2ml x 1 as a single dose. The second group received an&#xD;
      intramuscular injection of NaCl 0,9 mg/ml 2ml x 1 as a single dose. Symptom score and the use&#xD;
      of medication was registered daily during the pollen peak of the season, using an electronic&#xD;
      diary. The study was conducted during the spring of 2019.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Combined Medical- and Symptom score (CSMS)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Daily scoring of rhinoconjunctivitis symptoms (4 questions, 4-point scale. 0= no symptoms and 3=severe symptoms) and use of rescue medication (3-point scale. 0=no medication, 1= oral and/or topical (eyes) non sedative H1 antihistamines (H1A), 2= intranasal corticosteroids with/without H1A) during the birch pollen season.&#xD;
CSMS 6-point scale (0=no symptoms and no use of medication, 5= severe symptoms and use of intranasal corticosteroids with/without H1A)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean symptom score</measure>
    <time_frame>3 weeks</time_frame>
    <description>Daily scoring of rhinoconjunctivitis symptoms (4 questions, 4-point scale. 0= no symptoms and 3=severe symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on Quality of Life (QoL), SNOT</measure>
    <time_frame>3 weeks</time_frame>
    <description>Changes in Sino Nasal Outcome Test 22 (SNOT-22) at trial start, after 1 and 3 weeks respectively.&#xD;
22 questions, 6-point scale (0=no change in quality of life and 5=severe reduction in quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Quality of Life (QoL), RQLQ</measure>
    <time_frame>3 weeks</time_frame>
    <description>Changes in Juniper Rhinitis Quality of Life Questionnaire (RQLQ) at trial start, after 1 and 3 weeks respectively.&#xD;
28 questions, 7-point scale ((0=no change in quality of life and 6=severe reduction in quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Quality of Life (QoL), ACQ</measure>
    <time_frame>3 weeks</time_frame>
    <description>Changes in Asthma Control Questionnaire (ACQ) at trial start, after 1 and 3 weeks respectively.&#xD;
5 questions, 7-point scale ((0=no change in quality of life and 6=severe reduction in quality of life)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <condition>Hay Fever</condition>
  <condition>Pollen Allergy</condition>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Depo-Medrol (Methylprednisolone) 40 milligrams/milliliter, 2 milliliters as a single dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Chloride (NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0,9 milligrams/milliliter, 2 milliliters as a single dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MethylPREDNISolone 40 Mg/mL Injectable Suspension</intervention_name>
    <description>intramuscular injection</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>Depo-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 9 MG/ML Injectable Solution</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Sodium Chloride (NaCl)</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe birch pollen induced allergic rhinitis.&#xD;
&#xD;
          -  Signed informed consent according to International Council of Harmonisation/Good&#xD;
             Clinical Practice, and national/local regulations.&#xD;
&#xD;
          -  Women of considered childbearing potential (WOCBP) will only be included after a&#xD;
             negative highly sensitive pregnancy test according to CTFG recommendations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or nursing.&#xD;
&#xD;
          -  Autoimmune or collagen disease.&#xD;
&#xD;
          -  Cardiovascular disease.&#xD;
&#xD;
          -  Hepatic disease.&#xD;
&#xD;
          -  Renal disease.&#xD;
&#xD;
          -  Cancer.&#xD;
&#xD;
          -  Upper airway disease (non-allergic sinusitis, nasal polyposis, chronic obstructive-&#xD;
             and restrictive lung disease).&#xD;
&#xD;
          -  Medication with a possible side-effect of interfering with the immune response.&#xD;
&#xD;
          -  Previous immuno- or chemotherapy.&#xD;
&#xD;
          -  Chronic disease.&#xD;
&#xD;
          -  Major metabolic disease.&#xD;
&#xD;
          -  Alcohol or drug abuse.&#xD;
&#xD;
          -  Mental incapability of coping with the study.&#xD;
&#xD;
          -  Known or suspected allergy to the study product.&#xD;
&#xD;
          -  Suspicion of or confirmed bacterial infection.&#xD;
&#xD;
          -  Known allergy to the study drugs, &quot;rescue medication&quot;.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Olaf Cardell, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Lung-and Allergy Research</name>
      <address>
        <city>Lund</city>
        <state>Skane</state>
        <zip>22242</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Lars Olaf Cardell</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

